Researchers at the University of Chicago Medicine Comprehensive Cancer Center have discovered a novel approach for predicting treatment results in individuals with metastatic colorectal cancer. They can identify unique groupings that correspond to varied treatment results by integrating genetic biomarkers and clinical aspects of the tumor. The findings expand on prior research that discovered distinct molecular patterns in patients with a favorable subtype of colorectal liver metastases. In a clinical experiment, the researchers validated a new biomarker panel of 31 genes, which correctly identified the disease’s molecular subtype in 96% of patients. This data can be used to determine which patients will benefit the most from targeted therapies like as surgery or radiation therapy. The findings corroborate the “oligometastasis” concept, which states that cancer spread can occur in small groups.

To know more: About the original article click here.